Literature DB >> 20712014

Peroxiredoxins in colorectal neoplasms.

X Y Wu1, Z X Fu, X H Wang.   

Abstract

Peroxiredoxins (Prxs) are novel group proteins with efficient antioxidant capacity, and some of them also have effects on cell proliferation, differentiation, apoptosis, and chemotherapy and radiotherapy resistance. Altogether six distinct Prxs expressions were investigated in histological samples of colorectal neoplasm and the distant normal tissues and investigated associatedly with parameters such as clinical stage and lymphnodes metastasis. Normal colorectal tissues were almost negative for Prxs, except Prx4 (15/32). In colorectal cancer tissues, the most prominent reactivity was observed with Prx2 in 23/32 cases, while the corresponding figures for others was 21/32 (Prx1), 18/32 (Prx3, Prx5, Prx6) and 8/32 (Prx4). Prx1 (P=0.023), Prx2 (P=0.012), and Prx5 (P=0.028) were the isoforms that showed significantly increased expression in colorectal cancer patients with stage III or lymphnodes metastasis-positive cases. There was a significant relationship between the expression of Prx1 and Prx2 (rs=0.425, P=0.015) and between Prx3 and Prx4 (rs=0.364, P=0.041). Additionally, 8 cases were studied by western analysis. Prx1, 2, 3, 5 and 6 were particularly elevated in tumors compared to nonmalignant tissue as assessed by immunohistochemistry. It appeared that some Prxs were upexpression in colorectal cancer tissues and may have some prognostic significance; the induction of Prxs could be explained by increased production of reactive oxygen species in carcinomatous tissue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20712014     DOI: 10.14670/HH-25.1297

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  19 in total

Review 1.  The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.

Authors:  Lianqin Li; Ai-Qun Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-21       Impact factor: 4.553

2.  Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma.

Authors:  Ponlapat Yonglitthipagon; Chawalit Pairojkul; Yaovalux Chamgramol; Alex Loukas; Jason Mulvenna; Jeffrey Bethony; Vajarabhongsa Bhudhisawasdi; Banchob Sripa
Journal:  Hum Pathol       Date:  2012-03-24       Impact factor: 3.466

3.  Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer.

Authors:  Seulhee Han; Haiying Shen; Minhyung Jung; Bum-Soo Hahn; Byung Kwan Jin; Insug Kang; Joohun Ha; Wonchae Choe
Journal:  Oncol Lett       Date:  2012-03-16       Impact factor: 2.967

Review 4.  The beginning of GPX2 and 30 years later.

Authors:  R Steven Esworthy; James H Doroshow; Fong-Fong Chu
Journal:  Free Radic Biol Med       Date:  2022-07-05       Impact factor: 8.101

5.  Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.

Authors:  Jie Zhou; Weiwen Shen; Xiaojing He; Jing Qian; Shiyuan Liu; Guanzhen Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells' survival by protecting cells from oxidative stress.

Authors:  Weidong Lu; Zhongxue Fu; Hao Wang; Jihong Feng; Jinlai Wei; Jinbao Guo
Journal:  Mol Cell Biochem       Date:  2013-11-15       Impact factor: 3.396

7.  Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells.

Authors:  Y-G Wang; L Li; C-H Liu; S Hong; M-J Zhang
Journal:  Clin Transl Oncol       Date:  2013-10-09       Impact factor: 3.405

Review 8.  Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.

Authors:  Eva-Maria Hanschmann; José Rodrigo Godoy; Carsten Berndt; Christoph Hudemann; Christopher Horst Lillig
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

9.  The critical role of peroxiredoxin-2 in colon cancer stem cells.

Authors:  Linglong Peng; Yongfu Xiong; Rong Wang; Ling Xiang; He Zhou; Zhongxue Fu
Journal:  Aging (Albany NY)       Date:  2021-03-26       Impact factor: 5.682

10.  Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation.

Authors:  Ebony R Hoskins; Brian L Hood; Mai Sun; Thomas C Krivak; Robert P Edwards; Thomas P Conrads
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.